SG11202006217YA - Anti-claudin 18.2 antibodies - Google Patents
Anti-claudin 18.2 antibodiesInfo
- Publication number
- SG11202006217YA SG11202006217YA SG11202006217YA SG11202006217YA SG11202006217YA SG 11202006217Y A SG11202006217Y A SG 11202006217YA SG 11202006217Y A SG11202006217Y A SG 11202006217YA SG 11202006217Y A SG11202006217Y A SG 11202006217YA SG 11202006217Y A SG11202006217Y A SG 11202006217YA
- Authority
- SG
- Singapore
- Prior art keywords
- claudin
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G01N33/57525—
-
- G01N33/5753—
-
- G01N33/5758—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643035P | 2018-03-14 | 2018-03-14 | |
| US201962803297P | 2019-02-08 | 2019-02-08 | |
| PCT/CN2019/078150 WO2019174617A1 (en) | 2018-03-14 | 2019-03-14 | Anti-claudin 18.2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006217YA true SG11202006217YA (en) | 2020-07-29 |
Family
ID=67908599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006217YA SG11202006217YA (en) | 2018-03-14 | 2019-03-14 | Anti-claudin 18.2 antibodies |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11485782B2 (en) |
| EP (1) | EP3765522A4 (en) |
| JP (1) | JP2021515583A (en) |
| KR (1) | KR20200130831A (en) |
| CN (1) | CN112166123B (en) |
| AU (1) | AU2019235033A1 (en) |
| BR (1) | BR112020014591A2 (en) |
| CA (1) | CA3087423A1 (en) |
| IL (1) | IL277072A (en) |
| MX (1) | MX2020009514A (en) |
| RU (1) | RU2020128013A (en) |
| SG (1) | SG11202006217YA (en) |
| TW (1) | TW202003562A (en) |
| WO (1) | WO2019174617A1 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202006217YA (en) | 2018-03-14 | 2020-07-29 | Beijing Xuanyi Pharmasciences Co Ltd | Anti-claudin 18.2 antibodies |
| CN112534052B (en) | 2018-07-25 | 2024-09-20 | 奥美药业有限公司 | New IL-21 prodrug and method of use |
| EP3904386A4 (en) | 2018-12-28 | 2022-09-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | ANTIBODIES AND ITS USE |
| KR20210134321A (en) | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | Anti-claudin 18 antibodies and methods of use thereof |
| CA3149406A1 (en) * | 2019-08-20 | 2021-02-25 | Xueming Qian | Novel anti-cldn18.2 antibodies |
| CN112574307B (en) * | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | Anti-human Claudin18.2 antibody and its application |
| CN112707965A (en) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | Antibody targeting CLDN18.2 and preparation method and application thereof |
| KR102649942B1 (en) * | 2019-11-05 | 2024-03-25 | 라노바 메디신즈 리미티드 컴파니 | Antibody-drug conjugates targeting claudin 18.2 |
| AU2020410998A1 (en) * | 2019-12-23 | 2022-06-16 | Sotio Biotech A.S. | Tumor-specific Claudin 18.2 antibodies |
| AU2020414932B2 (en) * | 2019-12-27 | 2025-05-29 | Legend Biotech Ireland Limited | Claudin18.2 binding moieties and uses thereof |
| KR20220140786A (en) * | 2020-02-10 | 2022-10-18 | 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 | Claudin 18.2 Antibodies and Their Uses |
| WO2021160154A1 (en) * | 2020-02-10 | 2021-08-19 | 上海诗健生物科技有限公司 | Cldn18.2 antibody and use thereof |
| AU2021270940A1 (en) * | 2020-05-15 | 2022-12-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody drug conjugate, preparation method therefor and use thereof |
| MX2022014896A (en) * | 2020-05-25 | 2023-01-04 | Suzhou Transcenta Therapeutics Co Ltd | ANTI-CLDN18.2 ANTIBODIES AND USES FOR DIAGNOSIS THEREOF. |
| CA3178855A1 (en) * | 2020-06-19 | 2021-12-23 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-claudin18.2 antibody and use thereof |
| EP4168454A4 (en) * | 2020-06-23 | 2024-10-02 | Antengene Biologics Limited | Antibodies and methods for treating claudin-associated diseases |
| EP4180457A4 (en) * | 2020-07-13 | 2024-08-07 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cldn-18.2 antibody and use thereof |
| KR20230079397A (en) * | 2020-09-28 | 2023-06-07 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | Novel anti-Claudin18 antibody |
| AU2021405049A1 (en) * | 2020-12-23 | 2023-06-22 | Sotio Biotech A.S. | Tumor-specific claudin 18.2 antibody-drug conjugates |
| CA3211403A1 (en) * | 2021-02-19 | 2022-08-25 | Suzhou Transcenta Therapeutics Co., Ltd. | Anti-cldn18.2 antibody conjugates |
| CN117083299A (en) * | 2021-04-02 | 2023-11-17 | 原启生物科技(上海)有限责任公司 | CLDN18.2 antigen binding proteins and uses thereof |
| WO2022253155A1 (en) * | 2021-05-31 | 2022-12-08 | Shijiazhuang Yiling Pharmaceutical Co., Ltd. | Monoclonal antibodies against cldn18.2 and fc-engineered versions thereof |
| EP4393515A1 (en) * | 2021-08-26 | 2024-07-03 | Shanghai Junshi Biosciences Co., Ltd. | Anti-cldn-18.2 antibody-drug conjugate and use thereof |
| KR20240099308A (en) * | 2021-10-19 | 2024-06-28 | 바이오션, 인코포레이티드 | Antibodies binding to CLDN18.2 and uses thereof |
| US20250002576A1 (en) * | 2021-10-25 | 2025-01-02 | Fusion Pharmaceuticals Inc. | Claudin 18.2-binding antibodies and fragments thereof |
| CN116102649A (en) * | 2021-11-11 | 2023-05-12 | 上海生物制品研究所有限责任公司 | Anti-CLDN18.2 monoclonal antibody and its application |
| CN117777288A (en) * | 2022-09-29 | 2024-03-29 | 南京博望医药科技有限公司 | Anti-claudin 18.2 antibody |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024173384A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| CN116554328B (en) * | 2023-05-11 | 2023-09-29 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | A single-chain antibody, CAR, CAR-NK cell targeting TRBV12 and its application |
| CN119101162A (en) * | 2023-06-07 | 2024-12-10 | 江苏奥赛康生物医药有限公司 | An anti-CLDN18_2 antibody and in vitro diagnostic kit |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| CN120040544A (en) * | 2024-06-12 | 2025-05-27 | 南京农业大学 | Polypeptide specifically combined with endosulfan immune complex and application thereof |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4933294A (en) | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
| DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| ZA894792B (en) | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
| AU634167B2 (en) | 1988-06-24 | 1993-02-18 | Dow Chemical Company, The | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DK0463151T3 (en) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Generation of xenogenic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (en) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | Method for producing xenogeneic immunoglobulin and transgenic mouse |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| FI941572L (en) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Combination and method of use of anti-erbB-2 monoclonal antibodies |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| ATE503496T1 (en) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| JPH08500017A (en) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | Bispecific immune adhesin |
| ATE139900T1 (en) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR THE TREATMENT OF B CELL LYMPHOMA |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69637481T2 (en) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Human antibodies to IL-8 derived from immunized Xenomae |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6143559A (en) | 1996-11-18 | 2000-11-07 | Arch Development Corporation | Methods for the production of chicken monoclonal antibodies |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| ES2244066T3 (en) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | PROCEDURE AND COMPOSITIONS OF GALACTOSILATED GLICOPROTEINS. |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| PT1071700E (en) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2601882T5 (en) | 1999-04-09 | 2021-06-07 | Kyowa Kirin Co Ltd | Procedure to monitor the activity of an immunofunctional molecule |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| HU231090B1 (en) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Cells producing antibody compositions |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| WO2003084569A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Drug containing antibody composition |
| CN102911987B (en) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | The adorned cell of genome |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CA2481656A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost |
| DK2289936T3 (en) | 2002-12-16 | 2017-07-31 | Genentech Inc | IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF |
| WO2005014653A2 (en) | 2003-02-28 | 2005-02-17 | Protein Design Labs, Inc. | Humanized chicken antibodies |
| WO2005035586A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| WO2005035778A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE |
| DK2380910T3 (en) | 2003-11-05 | 2015-10-19 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| JP5756802B2 (en) | 2009-08-13 | 2015-07-29 | クリスタル バイオサイエンス インク．Ｃｒｙｓｔａｌ Ｂｉｏｓｃｉｅｎｃｅ Ｉｎｃ． | Transgenic animals producing antibodies with minimal CDRs |
| US9380769B2 (en) | 2011-05-24 | 2016-07-05 | Crystal Bioscience Inc. | Transgenic chicken comprising an inactivated immunoglobulin gene |
| US9394372B2 (en) | 2011-10-21 | 2016-07-19 | Crystal Bioscience Inc. | In vivo method for generating diversity in a protein scaffold |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| JP7587921B2 (en) * | 2016-07-08 | 2024-11-21 | クレージュ メディカル カンパニー，リミテッド | Anti-claudin 18A2 antibody and its applications |
| SG11202006217YA (en) | 2018-03-14 | 2020-07-29 | Beijing Xuanyi Pharmasciences Co Ltd | Anti-claudin 18.2 antibodies |
-
2019
- 2019-03-14 SG SG11202006217YA patent/SG11202006217YA/en unknown
- 2019-03-14 TW TW108108735A patent/TW202003562A/en unknown
- 2019-03-14 MX MX2020009514A patent/MX2020009514A/en unknown
- 2019-03-14 BR BR112020014591-2A patent/BR112020014591A2/en not_active Application Discontinuation
- 2019-03-14 US US16/980,294 patent/US11485782B2/en active Active
- 2019-03-14 EP EP19768583.7A patent/EP3765522A4/en not_active Withdrawn
- 2019-03-14 KR KR1020207027554A patent/KR20200130831A/en not_active Withdrawn
- 2019-03-14 AU AU2019235033A patent/AU2019235033A1/en not_active Abandoned
- 2019-03-14 RU RU2020128013A patent/RU2020128013A/en unknown
- 2019-03-14 CA CA3087423A patent/CA3087423A1/en active Pending
- 2019-03-14 CN CN201980016664.8A patent/CN112166123B/en active Active
- 2019-03-14 WO PCT/CN2019/078150 patent/WO2019174617A1/en not_active Ceased
- 2019-03-14 JP JP2020549599A patent/JP2021515583A/en active Pending
-
2020
- 2020-09-01 IL IL277072A patent/IL277072A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020009514A (en) | 2020-12-07 |
| EP3765522A1 (en) | 2021-01-20 |
| TW202003562A (en) | 2020-01-16 |
| CA3087423A1 (en) | 2019-09-19 |
| AU2019235033A1 (en) | 2020-07-30 |
| US20210009686A1 (en) | 2021-01-14 |
| KR20200130831A (en) | 2020-11-20 |
| IL277072A (en) | 2020-10-29 |
| BR112020014591A2 (en) | 2020-12-01 |
| CN112166123B (en) | 2022-09-30 |
| EP3765522A4 (en) | 2022-05-18 |
| JP2021515583A (en) | 2021-06-24 |
| WO2019174617A1 (en) | 2019-09-19 |
| RU2020128013A (en) | 2022-04-15 |
| US11485782B2 (en) | 2022-11-01 |
| CN112166123A (en) | 2021-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277072A (en) | Anti-claudin 18.2 antibodies | |
| IL276830A (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| SG10202111141WA (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| IL280780A (en) | Anti-tigit antibodies | |
| IL279321A (en) | Anti-sirpα antibody | |
| IL280013B1 (en) | Anti-il36r antibodies | |
| ZA202103061B (en) | Anti-cldn18.2 antibody and uses thereof | |
| IL279352A (en) | Il-11ra antibodies | |
| IL278010A (en) | Galectin-10 antibodies | |
| GB201817172D0 (en) | Antibody | |
| GB202110263D0 (en) | Anti-btla antibodies | |
| IL277030A (en) | Antibodies | |
| ZA202101177B (en) | Anti-btla antibody | |
| GB201811368D0 (en) | Antibody | |
| IL281594B2 (en) | Anti-klrg1 antibodies | |
| GB201806084D0 (en) | Antibodies | |
| GB202015822D0 (en) | 66.123.142648/01 | |
| GB201917115D0 (en) | . | |
| GB201819687D0 (en) | Mrbr.5 | |
| SG11202105718TA (en) | Modified antibodies | |
| GB201819952D0 (en) | Antibodies | |
| GB201817311D0 (en) | Antibodies | |
| GB201817309D0 (en) | Antibodies | |
| GB201817313D0 (en) | Antibodies | |
| GB201817312D0 (en) | Antibodies |